The management team and board of directors are composed of veteran biopharmaceutical and finance industry executives, including Samsara BioCapital founder
Citigroup is serving as the sole book-running manager for the offering. The Company has granted the underwriters a 45-day option to purchase up to an additional 1,500,000 Class A shares at the initial public offering price to cover over-allotments, if any.
The offering is being made only by means of a prospectus. When available, copies of the prospectus may be obtained from Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at (800) 831-9146.
A registration statement relating to the securities has been filed with, and declared effective by, the
Forward Looking Statements
This press release contains statements that constitute “forward-looking statements,” including with respect to the proposed initial public offering and the anticipated use of the net proceeds. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement for the Company’s offering filed with the
View original content to download multimedia:http://www.prnewswire.com/news-releases/jiya-acquisition-corp-announces-pricing-of-100-million-initial-public-offering-301176571.html
SOURCE Jiya Acquisition Corp.